Joint Research Links GLP-1 Medications to Hair Loss Risk
What happened
Joint research published by BMJ and NYU Langone Health indicates that individuals with type 2 diabetes taking GLP-1 receptor agonists, such as semaglutide and tirzepatide, face an increased risk of hair loss. Further findings from NYU Langone Health suggest that men with a genetic predisposition to hair loss on these drugs are about 7 percent more likely to experience increased hair shedding. Experts note that this hair loss is temporary, known as telogen effluvium, and is attributed to rapid weight loss rather than the medication itself.
From menshealth.com
Why it matters
The findings relate to the safety profile of GLP-1 medications, which are widely used for weight management and diabetes treatment. The research suggests that while the side effect is temporary, it may influence prescribing habits and patient acceptance of these treatments.
From menshealth.com
Who's involved
- BMJGlobal healthcare knowledge provider that published the research
- NYU Langone HealthHospital that contributed research on GLP-1 side effects
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- BMJSpeculative
The publication of this research might influence the demand for GLP-1 medications.
Keep exploring
The entities involved
-
BMJ
global healthcare knowledge provider, wholly owned subsidiary of the British Medical Association
Nothing else this week.
-
NYU Langone Health
hospital in New York, United States
Nothing else this week.